Atlas Trials

DNP-Modified Autologous Tumor Cell Vaccine for Resectable Non-Small Cell Lung Cancer

Clinical trial NCT00298298 · TERMINATED

Trial details

NCT number
NCT00298298
Sponsor
AVAX Technologies
Status
TERMINATED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Non-Small Cell Lung Cancer - Completely Resectable
Start date
2006-01-01
Primary completion
2014-01-01
Enrollment
6

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.